Immunology
Global

Immunology Experts

Tony Fiorino

MD, PHD CHIEF MEDICAL OFFICER AND CHIEF OPERATING
immunology
Pfizer
Belize

Biography

Tony joined Immune Pharmaceuticals in August 2017 from Triumvira Immunologics, an immuno-oncology company developing a novel engineered T cell platform, where he served as President and Chief Executive Officer. Prior to joining Triumvira, Dr. Fiorino was the Chief Executive Officer of BrainStorm Cell Therapeutics (NASDAQ:BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases. During his tenure, BrainStorm conducted a phase 2 trial of neurotrophic factor-secreting mesenchymal stem cells in amyotrophic lateral sclerosis, raised $25 million in equity capital, and uplisted to the NASDAQ. Prior to joining BrainStorm, he was the Founder, President and CEO of EnzymeRx, where he led the acquisition of a late-stage pre-clinical biologic and the development of the compound through phase 2 clinical trials and its subsequent sale to 3SBio. Before founding EnzymeRx, Dr. Fiorino worked as a biotechnology and pharmaceuticals analyst and portfolio manager at firms including JP Morgan, Citigroup, and Pequot Capital. Dr. Fiorino earned an MD and a PhD from the Albert Einstein College of Medicine, where he studied the differentiation of liver progenitor cells, and a BS from the Massachusetts Institute of Technology.

Research Interest

Tony joined Immune Pharmaceuticals in August 2017 from Triumvira Immunologics, an immuno-oncology company developing a novel engineered T cell platform, where he served as President and Chief Executive Officer. Prior to joining Triumvira, Dr. Fiorino was the Chief Executive Officer of BrainStorm Cell Therapeutics (NASDAQ:BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases. During his tenure, BrainStorm conducted a phase 2 trial of neurotrophic factor-secreting mesenchymal stem cells in amyotrophic lateral sclerosis, raised $25 million in equity capital, and uplisted to the NASDAQ. Prior to joining BrainStorm, he was the Founder, President and CEO of EnzymeRx, where he led the acquisition of a late-stage pre-clinical biologic and the development of the compound through phase 2 clinical trials and its subsequent sale to 3SBio. Before founding EnzymeRx, Dr. Fiorino worked as a biotechnology and pharmaceuticals analyst and portfolio manager at firms including JP Morgan, Citigroup, and Pequot Capital. Dr. Fiorino earned an MD and a PhD from the Albert Einstein College of Medicine, where he studied the differentiation of liver progenitor cells, and a BS from the Massachusetts Institute of Technology.

Global Experts from Belize

Global Experts in Subject

Share This Profile
Recommended Conferences
  • 12th International Conference on Allergy, Asthma & Clinical Immunology

    October 1-2, 2018 Moscow, Russia

  • World Congress and Expo on Immunology

    October 19-20, 2018 Baltimore, USA

  • 6th World Congress on Control and Prevention of HIV/AIDS, STDs & STIs

    October 29-30, 2018 San Francisco, USA

  • 3rd International Conference on Autoimmunity

    November 26-27, 2018 Dublin, UK

  • 13th World Congress on Virology

    December 3-4, 2018 Chicago, USA

  • 4th Antibodies, Antibiotics and Bio Therapeutics Congress

    December 05-06, 2018 Chicago, USA

  • 13th International Conference on Allergy and Clinical Immunology

    December 13-14 , 2018 Abu Dhabi, UAE

View more
Relevant Topics